No connection

Search Results

ECG

NEUTRAL
$136.06 Live
Everus Construction Group, Inc. · NYSE
Target $131.5 (-3.4%)
$38.52 52W Range $139.0

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$6.94B
P/E
34.45
ROE
38.3%
Profit margin
5.4%
Debt/Equity
0.59
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ECG exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and impressive growth metrics, including 60.2% YoY earnings growth. However, the stock is significantly overvalued, trading at $136.06—well above its Graham Number ($33.13) and Intrinsic Value ($116.53). While profitability is strong with an ROE of 38.34%, the technical trend is heavily bearish (10/100), suggesting the recent 232% one-year rally may have peaked. The valuation premium is high, and the current price exceeds the analyst target of $131.50.

Key Strengths

Exceptional earnings growth (60.2% YoY)
Strong Return on Equity (ROE) of 38.34%
Healthy balance sheet with low Debt/Equity (0.59)
Consistent earnings beats (3 of last 4 quarters) with high average surprise
Robust revenue growth (33.2% YoY)

Key Risks

Extreme valuation with a Price/Book ratio of 11.02
Trading at a significant premium to both Graham and Intrinsic values
Bearish technical trend (10/100) indicating potential price correction
Low profit margins (5.39%) typical of high-volume construction but risky
Lack of dividend yield for income support during volatility
AI Fair Value Estimate
Based on comprehensive analysis
$121.5
-10.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
56
Moderate
Value
30
Future
85
Past
90
Health
75
Dividend
0
AI Verdict
Growth-driven but overextended
Key drivers: High EPS growth, Strong ROE, Excessive P/B ratio, Bearish technicals
Confidence
90%
Value
30/100

Ref P/E 34.45, P/B 11.02, Graham $33.13

Positives
  • Forward P/E is slightly lower than current P/E
Watchpoints
  • Price far exceeds Graham Number ($33.13)
  • P/B ratio of 11.02 is excessive for Industrials
  • Price exceeds Intrinsic Value
Future
85/100

Ref Growth rates and Earnings surprises

Positives
  • 33% Revenue growth
  • 60% Earnings growth
  • Strong quarterly surprise track record
Watchpoints
  • Recent Q/Q EPS growth slight dip (-2.7%)
Past
90/100

Ref Historical price performance and EPS progression

Positives
  • 1Y return of +232.1%
  • Consistent upward trajectory in EPS over last 4 quarters
Watchpoints
  • Extreme volatility in 2024 earnings
Health
75/100

Ref Piotroski F-Score and Liquidity ratios

Positives
  • Piotroski F-Score 6/9 (Stable)
  • Current Ratio 1.76
  • Low Debt/Equity 0.59
Watchpoints
  • Altman Z-Score not provided
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$136.06
Analyst Target
$131.5
Upside/Downside
-3.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ECG and closest competitors.

Updated 2026-04-24
ECG
Everus Construction Group, Inc.
Primary
5Y
+177.7%
3Y
+177.7%
1Y
+232.1%
6M
+44.9%
1M
+10.4%
1W
+5.6%
AAO
AAON, Inc.
Peer
5Y
+72.1%
3Y
+40.5%
1Y
+7.6%
6M
+2.2%
1M
-18.3%
1W
-5.0%
ROA
Construction Partners, Inc.
Peer
5Y
+316.0%
3Y
+386.2%
1Y
+62.2%
6M
+9.2%
1M
+7.0%
1W
+5.7%
MID
The Middleby Corporation
Peer
5Y
-13.1%
3Y
+2.5%
1Y
+8.1%
6M
+8.1%
1M
-0.4%
1W
+5.6%
AL
Air Lease Corporation
Peer
5Y
+64.5%
3Y
+54.2%
1Y
+38.3%
6M
+11.7%
1M
+0.3%
1W
+0.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
34.45
Forward P/E
29.55
PEG Ratio
N/A
P/B Ratio
11.02
P/S Ratio
1.85
EV/Revenue
1.91
EV/EBITDA
24.39
Market Cap
$6.94B

Profitability

Profit margins and return metrics

Profit Margin 5.39%
Operating Margin 6.81%
Gross Margin 12.12%
ROE 38.34%
ROA 10.97%

Growth

Revenue and earnings growth rates

Revenue Growth +33.2%
Earnings Growth +60.2%
Q/Q Revenue Growth +33.15%
Q/Q Earnings Growth +60.4%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.59
Moderate
Current Ratio
1.76
Good
Quick Ratio
1.6
Excellent
Cash/Share
$2.99

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$1.0B
Gross Margin
11.6%
Op. Margin
6.8%
Net Margin
5.5%
Total Assets
$1.7B
Liabilities
$1.1B
Equity
$0.6B
Debt/Equity
1.74x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
49%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-02-24
$1.08
+40.6% surprise
2025-11-04
$1.11
+80.0% surprise
2025-08-12
$1.03
+74.6% surprise

Industrials Sector Comparison

Comparing ECG against 420 companies in the Industrials sector (34 bullish, 148 neutral, 238 bearish)
P/E Ratio
34.45
This Stock
vs
79.67
Sector Avg
-56.8% (Discount)
Return on Equity (ROE)
38.34%
This Stock
vs
-22.38%
Sector Avg
-271.3% (Below Avg)
Profit Margin
5.39%
This Stock
vs
6.48%
Sector Avg
-16.8% (Weaker)
Debt to Equity
0.59
This Stock
vs
2.74
Sector Avg
-78.4% (Less Debt)
Revenue Growth
33.2%
This Stock
vs
78.25%
Sector Avg
-57.6% (Slower)
Current Ratio
1.76
This Stock
vs
3.17
Sector Avg
-44.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

THIEDE JEFFREY S
Chief Executive Officer
Stock Award
2026-02-27
12,011 shares
ROSENTHAL DALE S
Director
Stock Award
2026-02-27
125 shares · $13,112
SANDERSON PAUL R
Officer
Stock Award
2026-02-27
2,456 shares
MARCY MAXIMILLIAN J
Chief Financial Officer
Stock Award
2026-02-27
2,774 shares
HUNKE JON B.
Officer
Stock Award
2026-02-27
929 shares
NOSBUSCH THOMAS D
Chief Operating Officer
Stock Award
2026-02-27
3,889 shares
HENDRICKS BRITNEY A
Officer
Stock Award
2026-02-27
1,830 shares
BEHRING JASON A
Officer
Stock Award
2026-02-27
934 shares
SZNEWAJS TIMOTHY RYAN
Officer
Stock Award
2026-02-27
1,424 shares
HERNANDEZ HELENA MERCEDES
Director
Buy
2025-12-08
250 shares · $23,045
ROSENTHAL DALE S
Director
Stock Award
2025-11-28
144 shares · $13,085
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-02

ECG filed an 8-K on April 2, 2026, likely to announce its first-quarter financial results.

DEF 14A
DEF 14A
2026-03-27

ECG filed a definitive proxy statement (DEF 14A) on March 27, 2026, providing shareholders with information regarding matters to be voted on at an upcoming meeting.

8-K/A
8-K/A
2026-03-18

ECG filed an amendment to a previously submitted Current Report on Form 8-K.

10-K
10-K
2026-02-25

ECG filed its annual 10-K report on February 25, 2026. Due to the absence of detailed text in the provided excerpts, specific financial highlights and risk factors cannot be determined.

8-K
8-K
2026-02-24

ECG filed an 8-K on February 24, 2026, likely to announce its annual financial results.

8-K
8-K
2026-01-21

ECG filed an 8-K on January 21, 2026, likely to announce its quarterly or annual financial results.

10-Q
10-Q
2025-11-05

As of September 30, 2025, ECG reported $1.93 billion in outstanding surety bonds, a decrease from $2.05 billion on December 31, 2024, with the majority of bonding concentrated in the E&M segment. The company faces significant off-balance sheet risks related to these performance guarantees, as it is required to indemnify sureties for expenses incurred if it fails to perform under its contracts.

8-K
8-K
2025-11-04

ECG filed an 8-K on November 4, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-08-13

ECG's outstanding surety bonds decreased to $1.89 billion as of June 30, 2025, from $2.05 billion at year-end 2024, with growth in T&D bonding partially offsetting a decline in E&M. The company faces significant off-balance sheet risks related to performance guarantees, letters of credit, and the obligation to indemnify sureties for expenses.

8-K
8-K
2025-08-12
8-K
8-K
2025-07-29
8-K
8-K
2025-05-28
8-K
8-K
2025-05-22
10-Q
10-Q
2025-05-15
8-K
8-K
2025-05-13
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
4 analysts
GLJ Research
2026-04-21
init
Hold
Stifel
2026-04-15
Maintains
Buy Buy
DA Davidson
2026-02-26
Maintains
Neutral Neutral
Freedom Broker
2026-02-26
Maintains
Buy Buy
DA Davidson
2026-02-25
Maintains
Neutral Neutral
Stifel
2026-01-26
Maintains
Buy Buy
Cantor Fitzgerald
2026-01-23
init
Neutral
Guggenheim
2026-01-22
init
Neutral
Freedom Broker
2025-12-17
init
Buy

Past News Coverage

Recent headlines mentioning ECG from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile